Current issues in chronic myeloid leukemia: monitoring, resistance, and functional cure.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  The Journal of the National Comprehensive Cancer Network

• Publication date

  2012-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.6004/JNCCN.2012.0184PMID 23055247
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Nilotinib versus imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd 3-year (yr) follow-up (f/u).

  2012cited by this paper
• Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.

  2012cited by this paper
• Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib.

  2012cited by this paper
• Subcutaneous omacetaxine mepesuccinate in patients with chronic phase (CP) or accelerated phase (AP) chronic myeloid leukemia (CML) resistant/intolerant to two or three approved tyrosine-kinase inhibitors (TKIs).

  2012cited by this paper
• BELA trial update: Bosutinib (BOS) versus imatinib (IM) in patients (pts) with newly diagnosed chronic phase chronic myeloid leukemia (CP CML) after 30 months of follow-up.

  2012cited by this paper
• Omacetaxine mepesuccinate in chronic-phase chronic myeloid leukemia (CML) in patients resistant, intolerant, or both to two or more tyrosine-kinase inhibitors (TKIs).

  2012cited by this paper
• Preview : Published ahead of advance online publication Standardized definitions of molecular response in chronic myeloid leukemia

  2012cited by this paper
• Dasatinib versus imatinib (IM) in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): DASISION 3-year follow-up.

  2012cited by this paper
• Switch to nilotinib versus continued imatinib in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) with detectable BCR-ABL after 2 or more years on imatinib : ENESTcmr 12-month (mo) follow-up

  2012cited by this paper
• Six-year (yr) follow-up of patients (pts) with imatinib-resistant or -intolerant chronic-phase chronic myeloid leukemia (CML-CP) receiving dasatinib.

  2011cited by this paper
• Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia

  2011cited by this paper
• Bosutinib (BOS) versus imatinib (IM) in patients (pts) with chronic phase chronic myeloid leukemia (CP CML) in the BELA trial: 18-month follow-up.

  2011cited by this paper
• Bosutinib Versus Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia – BELA Trial: 24-Month Follow-up

  2011cited by this paper
• BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia

  2011cited by this paper
• Activity of Bosutinib by Baseline and Emergent Mutation Status in Philadelphia Chromosome–Positive Leukemia Patients with Resistance or Intolerance to Other Tyrosine Kinase Inhibitors

  2011cited by this paper
• Dasatinib and Imatinib-Induced Reductions in BCR-ABL Transcript Levels Below 10% At 3 Months Are Associated with Improved Responses in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Analysis of Molecular Response Kinetics in the DASISION Trial

  2011cited by this paper
• Bcr-Abl Mutations in Chronic Myeloid Leukemia - Impact on Survival and Treatment with Second Generation Inhibitors– A Study on Behalf of Latin American Leukemia Net (Lalnet)

  2011cited by this paper
• Initial Findings From the PACE Trial: A Pivotal Phase 2 Study of Ponatinib in Patients with CML and Ph+ ALL Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I Mutation

  2011cited by this paper
• Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia.

  2011cited by this paper
• Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia.

  2011cited by this paper
• Sensitive detection of BCR-ABL1 mutations in patients with chronic myeloid leukemia after imatinib resistance is predictive of outcome during subsequent therapy.

  2011cited by this paper
• Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia

  2011cited by this paper
• Molecular and Cytogenetic Response After 3 Months of Imatinib Treatment Is Predictive for the Risk of Disease Progression and Death in Newly Diagnosed Chronic Myeloid Leukemia Patients – a Follow-up Analysis of the German CML Study IV

  2011cited by this paper
• Discontinuation of Imatinib in Patients with Chronic Myeloid Leukemia Who Have Maintained Complete Molecular Response: Update Results of the STIM Study

  2011cited by this paper
• Subcutaneous Omacetaxine in Chronic or Accelerated Chronic Myeloid Leukemia Resistant to Two or More Tyrosine-Kinase Inhibitors Including Imatinib,

  2011cited by this paper
• Kill one bird with two stones: potential efficacy of BCR-ABL and autophagy inhibition in CML.

  2011cited by this paper
• Minimal residual disease and discontinuation of therapy in chronic myeloid leukemia: can we aim at a cure?

  2011cited by this paper
• Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations.

  2011cited by this paper
• Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.

  2010cited by this paper
• Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib.

  2010cited by this paper
• The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors.

  2010cited by this paper
• Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.

  2010cited by this paper
• Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.

  2010cited by this paper
• Association of early molecular response to nilotinib with probability of cytogenetic response in chronic myeloid leukemia patients (pts) who fail imatinib.

  2010cited by this paper
• Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

  2010cited by this paper
• Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia

  2010cited by this paper
• A Randomized Phase II Trial of Dasatinib 100 Mg Vs Imatinib 400 Mg In Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP): The S0325 Intergroup Trial

  2010cited by this paper
• Hedgehog pathway activation in chronic myeloid leukemia: A promise for a novel combination therapeutic approach?

  2010cited by this paper
• Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia.

  2010cited by this paper
• Inhibitory Effects of Omacetaxine on Leukemic Stem Cells and BCR-ABL-Induced Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia in Mice

  2009cited by this paper
• International randomized study of interferon Vs STI571 (IRIS) 8-year follow up: Sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib

  2009cited by this paper
• Combination of the Hedgehog Pathway Inhibitor LDE225 and Nilotinib Eliminates Chronic Myeloid Leukemia Stem and Progenitor Cells.

  2009cited by this paper
• Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia.

  2009cited by this paper
• Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.

  2009cited by this paper
• AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance.

  2009cited by this paper
• Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?

  2009cited by this paper
• Update On Imatinib-Resistant Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) On Nilotinib Therapy at 24 Months: Clinical Response, Safety, and Long-Term Outcomes.

  2009cited by this paper
• Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long‐term outcome of patients with early chronic myeloid leukemia in chronic phase

  2009cited by this paper
• NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia.

  2009cited by this paper
• Safety and Efficacy of Subcutaneous-Administered Omacetaxine Mepesuccinate in Chronic Myeloid Leukemia (CML) Patients Who Are Resistant or Intolerant to Two or More Tyrosine Kinase Inhibitors – Results of A Multicenter Phase 2/3 Study.

  2009cited by this paper
• Harmonization of molecular monitoring of CML therapy in Europe

  2009cited by this paper
• Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression.

  2008cited by this paper
• Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia.

  2008cited by this paper
• Homo-Harringtonine (Omacetaxine mepesuccinate) Induces a Dramatic and Sustained Reduction of BCR-ABLT315I mutated Transcripts in Chronic Phase Chronic Myelogenous Leukemia Patients Resistant to Tyrosine Kinase Inhibitors.

  2008cited by this paper
• molecule Beyond the increasing complexity of the immunomodulatory HLA-G

  2008cited by this paper
• Sprycel for Chronic Myeloid Leukemia and Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia Resistant to or Intolerant of Imatinib Mesylate

  2008cited by this paper
• European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor.

  2008cited by this paper
• Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity.

  2007cited by this paper
• Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy.

  2007cited by this paper
• Why do chronic myelogenous leukemia stem cells survive allogeneic stem cell transplantation or imatinib: does it really matter?

  2006cited by this paper
• Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.

  2006cited by this paper
• Molecular monitoring of BCR-ABL as a guide to clinical management in chronic myeloid leukaemia.

  2006cited by this paper
• Contribution of ABL Kinase Domain Mutations to Imatinib Resistance in Different Subsets of Philadelphia-Positive Patients: By the GIMEMA Working Party on Chronic Myeloid Leukemia

  2006cited by this paper
• Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(ϕ)-LMC GROUP)

  2006cited by this paper
• Imatinib dose increase up to 1200 mg daily can induce new durable complete cytogenetic remissions in relapsed Ph+ chronic myeloid leukemia patients

  2005cited by this paper
• BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571.

  2003cited by this paper
• SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice.

  2003cited by this paper
• Complete cytogenetic and molecular responses to interferon‐α‐based therapy for chronic myelogenous leukemia are associated with excellent long‐term prognosis

  2003cited by this paper
• Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.

  2003cited by this paper
• Follow-up of complete cytogenetic remission in patients with chronic myeloid leukemia after cessation of interferon alfa.

  2002cited by this paper
• Imatinib mesylate--a new oral targeted therapy.

  2002cited by this paper
• Clinical Trials and Observations

  1996cited by this paper
• Pu.1-dependent Transcription Gata-1 Interacts with the Myeloid Pu.1 Transcription Factor and Represses

  year unknowncited by this paper

• Mechanisms and signaling pathways of tyrosine kinase inhibitor resistance in chronic myeloid leukemia: A comprehensive review

  2025cites this paper
• Imatinib in Targeted Therapy: Advances in Biomedical Applications and Drug Delivery Systems

  2025cites this paper
• Potential therapeutic targets in chronic myeloid leukemia

  2025cites this paper
• Investigation of TSRP reverses imatinib resistance through the PI3K / Akt pathway in chronic myeloid leukemia

  2024cites this paper
• Oxidative lipid damage by naringenin selectively sensitizes chronic myeloid leukemia cell lines and patient samples to Bcr-Abl tyrosine kinase inhibitors.

  2024cites this paper
• Bayesian Learning of Personalized Longitudinal Biomarker Trajectory

  2023cites this paper
• A Pragmatic Approach to Managing Long-Term Adverse Effects in Chronic Myeloid Leukemia Treatment

  2023cites this paper
• Psychological Factors Affecting the Willingness to Accept a Possible Tyrosine Kinase Inhibitor (TKI) Discontinuation in Chronic Myeloid Leukaemia (CML) Patients

  2022cites this paper
• Psychological Factors Affecting the Willingness to Accept a Possible Tyrosine Kinase Inhibitor (TKI) Discontinuation in Chronic Myeloid Leukaemia (CML) Patients

  2022cites this paper
• Evaluation of the combined effect of naringin and imatinib in philadelphia positive chronic myeloid leukemia

  2022cites this paper
• JAK inhibitors and COVID-19

  2022cites this paper
• A retrospective analysis of clinicopathological features and treatment outcomes of patients with chronic myeloid leukemia at a tertiary hospital

  2021cites this paper
• Combination of axitinib with dasatinib improves the outcome of a chronic myeloid leukemia patient with BCR-ABL1 T315I mutation.

  2020cites this paper
• Impact of Additional Cytogenetic Abnormalities on the Clinical Behavior of Patients With Chronic Myeloid Leukemia: Report on a Latin American Population.

  2019cites this paper
• Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy

  2018cites this paper
• Co-Occurrence of Acromegaly and Hematological Disorders: A Myth or Common Pathogenic Mechanism

  2017cites this paper
• CT-721, a Potent Bcr-Abl Inhibitor, Exhibits Excellent In Vitro and In Vivo Efficacy in the Treatment of Chronic Myeloid Leukemia

  2017cites this paper
• The choice dilemma in chronic hematological conditions: Why choosing is not only a medical issue? A psycho-cognitive perspective.

  2016cites this paper
• Simplifying procedure for prediction of resistance risk in CML patients - Test of sensitivity to TKI ex vivo.

  2016cites this paper
• Nowe metody diagnostyczne w prognozowaniu i śledzeniu odpowiedzi na leczenie inhibitorami kinaz tyrozynowych przewlekłej białaczki szpikowej

  2016cites this paper
• Bosutinib Therapy in Patients With Chronic Myeloid Leukemia: Practical Considerations for Management of Side Effects

  2016cites this paper
• The human Smoothened inhibitor PF-04449913 induces exit from quiescence and loss of multipotent Drosophila hematopoietic progenitor cells

  2016cites this paper
• Rationale and Protocol of CML Study: Cognitive and Emotional Impact of Discontinuation of Therapy in Patients with Chronic Myeloid Leukemia

  2016cites this paper
• Fluorescent In Situ Hybridization Monitoring and Effect of Detected Early Responses in the Outcome of Patients With Chronic Phase Chronic Myeloid Leukemia: A Report From a Latin American Country.

  2016cites this paper
• Use of the Word “Cure” in the Oncology Literature

  2015cites this paper
• Apport de la modélisation et des simulations de dynamique moléculaire à la description de STAT5 comme cible pour moduler la signalisation oncogénique

  2015cites this paper
• miRNAs as Biomarkers in Chronic Myelogenous Leukemia

  2015cites this paper
• The role of stem cell transplantation for chronic myelogenous leukemia in the 21st century.

  2015cites this paper
• Minimal residual disease monitoring: the new standard for treatment evaluation of haematological malignancies?

  2014cites this paper
• Reply: The BIM deletion polymorphism cannot account for intrinsic TKI resistance of Chinese individuals with chronic myeloid leukemia

  2014cites this paper
• Discontinuation of tyrosine kinase inhibitors and new approaches to target leukemic stem cells: treatment-free remission as a new goal in chronic myeloid leukemia.

  2014cites this paper
• Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors

  2014cites this paper
• Chronic myeloid leukaemia: A paradigm shift in management.

  2014cites this paper
• Practice gaps and barriers to optimal care of hematologic malignancies in the United States.

  2014cites this paper
• A Case of Isolated Lymphoblastic Relapse of the Central Nervous System in a Patient with Chronic Myelogenous Leukemia Treated with Imatinib

  2014cites this paper
• The BIM deletion polymorphism cannot account for intrinsic TKI resistance of Chinese individuals with chronic myeloid leukemia

  2014cites this paper
• Ponatinib: A Review of Its Use in Adults with Chronic Myeloid Leukaemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukaemia

  2014cites this paper
• Determinants of survival in patients with chronic myeloid leukaemia treated in the new era of oral therapy: findings from a UK population-based patient cohort

  2014cites this paper
• Prevalence of Anal Human Papillomavirus Infection Among HIV-Infected Women From India

  2014cites this paper
• Co-operating STAT5 and AKT signaling pathways in chronic myeloid leukemia and mastocytosis: possible new targets of therapy

  2014influential citation
• Words matter: Discussing research towards an HIV cure in research and clinical contexts.

  2014cites this paper
• A SMO inhibitor drug reduces the progenitor cell's maintenance in the Drosophila hematopoietic organ: a novel model to study Chronic Myelogenous Leukemia relapse

  2014influential citation
• Monitoring response to tyrosine kinase inhibitor therapy, mutational analysis, and new treatment options in chronic myelogenous leukemia.

  2013cites this paper
• An Observational study of Non-adherence in Patients with Chronic Myeloid Leukemia on Treatment with Imatinib – Prevalence, Predictors and Outcomes.

  2013cites this paper
• Chapter Twenty-Eight – To Market, To Market—2012

  2013cites this paper
• Allogeneic Stem Cell Transplantation for Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors- What are the Limitations?

  2013cites this paper
• Alternative approaches to eradicating the malignant clone in chronic myeloid leukemia: tyrosine-kinase inhibitor combinations and beyond.

  2013cites this paper
• Overcoming resistance in chronic myeloid leukemia

  2013cites this paper
• Stem cell clonality -- theoretical concepts, experimental techniques, and clinical challenges.

  2013cites this paper
• Bosutinib

  2013influential citation
• Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months

  2013cites this paper
• Bosutinib in the management of chronic myelogenous leukemia

  2013cites this paper
• What challenges remain in chronic myeloid leukemia research?

  2013cites this paper
• Emerging Therapeutic Strategies for Targeting Chronic Myeloid Leukemia Stem Cells

  2013cites this paper
• Bosutinib in the management of chronic myelogenous leukemia

  2013cites this paper
• Bosutinib in the management of chronic myelogenous leukemia

  2013cites this paper
• Physiologic hypoxia promotes maintenance of CML stem cells despite effective BCR-ABL1 inhibition.

  2011cites this paper